Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular, Oncologie Form Cancer Drug Biomarker Partnership

NEW YORK (GenomeWeb) — HTG Molecular Diagnostics announced today that it has signed a master agreement to help Oncologie develop biomarkers for its immuno-oncology drug candidates.

Specific terms of the deal were not disclosed.

Oncologie currently has two drugs in its pipeline: the phase II immune-modulatory monoclonal antibody bavituximab, and the phase III immunomodulator and toll-like receptor 9 agonist lefitolimod. HTG offers next-generation sequencing-based molecular profiling instruments and assays, as well as related lab services.

"We believe HTG's technology and assay development capabilities will assist our clinical development efforts as we strive to bring innovative new medicines to cancer patients globally," Oncologie Founder and CEO Laura Benjamin said in a statement.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.